RecruitingPhase 4NCT05282277

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

Examining the Effects of Estradiol on Neural and Molecular Response to Rewards in Perimenopausal-Onset Anhedonia and Psychosis


Sponsor

University of North Carolina, Chapel Hill

Enrollment

103 participants

Start Date

Apr 20, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This proposal will examine the effects of estradiol administration on perimenopausal-onset (PO) anhedonia and psychosis symptoms as well as on brain function using simultaneous positron emission tomography and functional magnetic resonance imaging (PET-MR).


Eligibility

Sex: FEMALEMin Age: 45 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This study investigates whether estradiol (a form of estrogen) given via skin patch can improve mood and reduce depression-like symptoms (particularly loss of pleasure, called anhedonia) in women going through the transition to menopause. Brain scans and blood tests are used to understand how estrogen affects the brain's reward system. **You may be eligible if...** - You are a woman aged 44–55 in the late menopausal transition (you've missed at least 2 periods or had no period for 60+ days) - You are not currently on any psychiatric medications or hormone therapy - You have symptoms of anhedonia (loss of pleasure or motivation) or mild psychosis that started during your menstrual changes - Your symptoms are clinically significant enough to impact daily life **You may NOT be eligible if...** - You have a history of breast or ovarian cancer, or carry the BRCA1/2 gene mutation - You have had psychiatric illness before menopause started (prior to the current episode) - You have heart, liver, or kidney disease - You have a peanut allergy or cannot have MRI scans (e.g., metal implants) - You are currently using psychotropic medications, hormones, or anti-inflammatory drugs frequently Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTransdermal Estradiol

Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.

DRUGMicronized Progesterone

Participants will receive an additional week of micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.

DRUGMatching Placebo Patch

Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks

DRUGRaclopride C11

All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.


Locations(1)

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05282277


Related Trials